BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 37187202)

  • 1. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
    Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
    Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of urinary diversion type on urethral recurrence following radical cystectomy for bladder cancer: propensity score matched and weighted analyses of retrospective cohort.
    Yu J; Lee CU; Chung JH; Song W; Kang M; Jeon HG; Jeong BC; Seo SI; Jeon SS; Sung HH
    Int J Surg; 2024 Feb; 110(2):700-708. PubMed ID: 38000052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
    Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
    Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
    Kang NW; Feng YH; Lin KL; Chen YC; Ho CH; Yang CC
    Cancer Med; 2024 Jan; 13(2):e6972. PubMed ID: 38379322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
    Softness K; Kaul S; Fleishman A; Efstathiou J; Bellmunt J; Kim SP; Korets R; Chang P; Wagner A; Olumi AF; Gershman B
    Urol Oncol; 2022 Jun; 40(6):272.e1-272.e9. PubMed ID: 35058142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study.
    Vetterlein MW; Gild P; Kluth LA; Seisen T; Gierth M; Fritsche HM; Burger M; Protzel C; Hakenberg OW; von Landenberg N; Roghmann F; Noldus J; Nuhn P; Pycha A; Rink M; Chun FK; May M; Fisch M; Aziz A;
    BJU Int; 2018 Jan; 121(1):101-110. PubMed ID: 28905486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.
    Zhong J; Switchenko J; Jegadeesh NK; Cassidy RJ; Gillespie TW; Master V; Nieh P; Alemozaffar M; Kucuk O; Carthon B; Filson CP; Bilen MA; Jani AB
    Am J Clin Oncol; 2019 Jan; 42(1):36-41. PubMed ID: 29912804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
    Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
    Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
    Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
    JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
    Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
    JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of robot-assisted vs. open radical cystectomy.
    Hanna N; Leow JJ; Sun M; Friedlander DF; Seisen T; Abdollah F; Lipsitz SR; Menon M; Kibel AS; Bellmunt J; Choueiri TK; Trinh QD
    Urol Oncol; 2018 Mar; 36(3):88.e1-88.e9. PubMed ID: 29277584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
    Shimizu F; Muto S; Taguri M; Ieda T; Tsujimura A; Sakamoto Y; Fujita K; Okegawa T; Yamaguchi R; Horie S
    Int J Urol; 2017 May; 24(5):367-372. PubMed ID: 28281310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.
    Fischer-Valuck BW; Rao YJ; Rudra S; Przybysz D; Germino E; Samson P; Baumann BC; Gay H; Michalski J
    J Urol; 2018 Feb; 199(2):416-423. PubMed ID: 28842247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
    Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
    Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study.
    Brück K; Meijer RP; Boormans JL; Kiemeney LA; Witjes JA; van Hoogstraten LMC; van der Heijden MS; Donders AR; Franckena M; Uyl de Groot CA; Leliveld AM; Aben KKH; Hulshof MCCM
    Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):41-49. PubMed ID: 37517601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
    Necchi A; Pond GR; Smaldone MC; Pal SK; Chan K; Wong YN; Viterbo R; Sonpavde G; Harshman LC; Crabb S; Alva A; Chowdhury S; De Giorgi U; Srinivas S; Agarwal N; Bamias A; Baniel J; Golshayan AR; Ladoire S; Sternberg CN; Cerbone L; Yu EY; Bellmunt J; Vaishampayan U; Niegisch G; Hussain S; Bowles DW; Morales-Barrera R; Milowsky MI; Theodore C; Berthold DR; Sridhar SS; Powles T; Rosenberg JE; Galsky MD;
    Eur Urol Focus; 2018 Dec; 4(6):937-945. PubMed ID: 28753879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Royce TJ; Liu Y; Milowsky MI; Efstathiou JA; Jani AB; Fischer-Valuck B; Patel SA
    Clin Genitourin Cancer; 2021 Aug; 19(4):362-368. PubMed ID: 33839040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.